APT-VEGA_KI: All Polyethylene Tibia-VEGA Kiel
Study Details
Study Description
Brief Summary
Obligatory Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation For this PMCF only CE-marked medical devices will be used within their intended purpose and no additional invasive or other stressful examinations are to be carried out (acc. to MPG §23b).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This non-interventional clinical study (NIS) is conducted to clinically confirm the safety and performance of the Aesculap® APT VEGA System® PS components under routine conditions. The VEGA System® PS is an established TKA design, and there is a long-lasting experience in the use of PE for TKA in general and for APT components in particular; thus a NIS is thought to be sufficient to give the required confirmation. For this NIS only CE-marked medical devices will be used within their intended purpose and no additional invasive or other stressful examinations are to be carried out (acc. to MPG §23b). As part of the post marketing surveillance plan an obligatory Post-Marketing Clinical Follow-up (PMCF) is required for the product under investigation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| All-Poly All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components |
Device: All-Poly
Implantation of the VEGA PS using all-polyethylene tibia components
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Revision Rate [5 years]
The objective of the study is to collect clinical midterm outcome information on the product under investigation when used in routine clinical practice.
Secondary Outcome Measures
- Complication/Adverse Event rate [5 years]
- KOOS (Knee Osteoarthritis Outcome Score) [5 years]
Changes of the total Knee injury and Osteoarthritis Outcome Score (KOOS) from the preoperative baseline to the 5-year postoperative
- KSS (Knee Society Score) [5 years]
Changes of the Knee Society Score (KSS) with its Knee and Functional Score (KS and FS) from the preoperative baseline to the 5-year postoperative assessment
- SF-12® Health Survey (SF-12) [5 years]
Changes of the total SF-12® Health Survey (SF-12) components Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) from the preoperative baseline to the 5-year postoperative assessment
- Pain [5 years]
Changes of anterior knee pain according to the Waters and Bentley rating system from the preoperative baseline to the 5-year postoperative assessment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients requiring primary TKA because of severe knee joint conditions that cannot be treated through other therapies;
-
degenerative osteoarthritis;
-
rheumatoid arthritis;
-
posttraumatic arthritis;
-
symptomatic knee instability;
-
knee stiffness or deformation of the knee joint;
-
Age ≥ 18 years;
-
Patient signed informed consent
Exclusion Criteria:
-
Age younger than 18 years
-
Any prior joint replacement at the index knee
-
Unable or unwilling to return for postoperative follow-up
-
Patient did not sign informed consent
-
Joint conditions that can be treated by reconstructive surgery (e.g. osteotomy)
-
Acute or chronic infections near the joint, or systemic infections
-
Secondary diseases that could influence joint implant functionality
-
Systemic diseases and metabolic disorders
-
Severe osteoporosis or osteomalacia
-
Severely damaged bone structures that could prevent stable implantation of implant components
-
Bone tumors in the region of implant fixation
-
Bone malformations, axial misalignments or other bone conditions that rule out implantation of a prosthetic joint
-
Expected overload on the joint implant, especially due to high patient weight or intense physical strain and activity
-
Dependency on pharmaceutical drugs, drug abuse, or alcoholism
-
Fever, infection or inflammation (systemic or local)
-
Pregnancy
-
Mental illness
-
Severe osteopenia (or any other medical or surgical finding) that would preclude any benefit from the implants
-
Combination with implant components from other manufacturers
-
Inadequate patient compliance
-
Foreign body sensitivity to the implant materials
-
All cases not listed under indications
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MEDBALTIC GmbH c/o Mare Klinikum | Kiel | Germany | 24119 |
Sponsors and Collaborators
- Aesculap AG
- Frictionless GmbH, Kiel
Investigators
- Principal Investigator: Ludger Gerdesmeyer, Professor, orthopedics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AAG-O-H-1527